H. Martin Seidel

Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974

Jun Liu, Shifeng Pan, Mindy H. Hsieh et al. · Proceedings of the National Academy of Sciences · 2013 · 819 citations · Full text

Wnt Signaling, Tumor Biology, Signaling Pathway +19

Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity.

H. Martin Seidel, Lawrence H. Milocco, Peter Lamb et al. · Proceedings of the National Academy of Sciences · 1995 · 422 citations · Full text

Genetics, Signal Transducers, Immunology +25

Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-<i>N</i>2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-<i>N</i>4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

Thomas H. Marsilje, Wei Pei, Bei Chen et al. · Journal of Medicinal Chemistry · 2013 · 405 citations · Full text

Chemoprevention Strategy, Pharmacotherapy, Structure–activity Relationships +21

Rapid activation of the STAT3 transcription factor by granulocyte colony-stimulating factor

SS Tian, Peter Lamb, H. Martin Seidel et al. · Blood · 1994 · 240 citations · Full text

Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)

David C. Tully, Paul V. Rucker, D. CHIANELLI et al. · Journal of Medicinal Chemistry · 2017 · 224 citations · Full text

Pathology, Farnesoid X Receptor, Pharmacotherapy +20